Altos Labs Emerges from Stealth Mode with $3B in Initial Funding
Altos Labs has emerged from stealth mode with a record-breaking $3B in initial funding from undisclosed investors. The company was quietly formed last year with a focus on cellular rejuvenation programming in an effort to restore cell health and reverse disease, injury, and disabilities. Altos's development tools will include computational science, machine learning, and artificial intelligence, combined with expertise from a team of both academic and industry researchers specialized in areas of stem cell science, tissue and organ regeneration, and molecular research. Organized into two institutes - the Institutes of Science and the Institute of Medicine - Altos will be based in the US and UK, with a presence in Japan as well. The Altos executive team will be composed of Hal Barron, MD (incoming CEO effective August 1, 2022 after he leaves his post as President of R&D and Chief Scientific Officer at GSK), Rick Klausner, MD (Chief Scientist and Founder; former director of the National Cancer Institute), Hans Bishop (President and Founder; former CEO of GRAIL and Juno Therapeutics), and Ann Lee-Karlon, PhD (Chief Operating Officer; former Senior Vice President at Genentech).
- Artificial Intelligence
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Venture Financing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.